The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Discover 9 promising small molecule drug discovery companies that recently raised funding for their potentially breakthrough ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did ...

As researchers work to improve treatment of Alzheimer's disease, new research by UCLA Health identified a candidate drug that ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...